The system includes a QX200 droplet generator and reader, dedicated computer, QuantaSoft software and associated component consumables. For over six decades, Bio-Rad has served life science research ...

Citi upgrades Bio-Rad Laboratories (BIO) to buy, downgrades Hologic (HOLX) to neutral and Charles River Laboratories (CRL) to ...

Fintel reports that on October 1, 2024, Citigroup upgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Neutral to ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $378.4, a high ...

With a market cap of $9.5 billion, Bio-Rad Laboratories, Inc. (BIO) operates in the healthcare and life sciences industry.

Bio-Rad Laboratories is buying back a considerable amount of its own stock given the current valuation and growth prospects.

A federal jury Monday awarded the former general counsel of Bio-Rad Laboratories $8 million in back pay and damages — which will increase to $11 million — for whistleblower retaliation involving ...

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo ...

The system includes a QX200 droplet generator and reader, dedicated computer, QuantaSoft software and associated component consumables. For over six decades, Bio-Rad has served life science research ...

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...